• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Zenas BioPharma (ZBIO) Could Be 41% Undervalued As FDA And Trial Catalysts Near

    Simply Wall St·10/31/2026 01:29:35
    Listen to the news

    Regulatory and Clinical Milestones Come Into Focus

    Zenas BioPharma (ZBIO) is heading into a packed catalyst window as investors watch an upcoming FDA decision on obexelimab for IgG4-related disease, alongside a parallel European review.

    Attention is also gathering around two clinical readouts expected this quarter: Phase II SunStone data in systemic lupus erythematosus and Phase I safety results for oral IL-17AA/AF inhibitor ZB021. Both could reshape how the pipeline is prioritized.

    Despite a busy calendar of catalysts, Zenas BioPharma’s share price has eased over the year, with a year-to-date share price return of 17.71% in decline and a 1-year total shareholder return also down 9.15%.

    Scan other clinical-stage opportunities that are setting up for their own catalyst runs with our hand-picked 18 high quality undiscovered gems that share Zenas BioPharma’s early-stage risk and reward profile.

    Zenas BioPharma trades well below consensus targets after a year of share price pressure. Is that discount a cushion against clinical and regulatory risk, or a warning that caution is warranted?

    Most Popular Narrative: 41% Undervalued

    Analysts tracking Zenas BioPharma see a big gap between the current $28.39 share price and their narrative fair value of $47.88, and that gap rests heavily on how obexelimab and the early commercial build play out over the next few years.

    The accepted Biologics License Application for obexelimab in IgG4-RD with a May 27, 2027 PDUFA date and planned EMA filing in the second half of 2026 positions Zenas BioPharma for a potential first commercial product that could start to offset current net losses and support future earnings.

    See why 1 investors see Zenas BioPharma as 41% undervalued.

    Result: Fair Value of $47.88 (UNDERVALUED)

    Still, the Zenas BioPharma story leans heavily on turning current losses of $484.4 million and rapid cash use into meaningful revenue before funding flexibility tightens.

    Find out about the key risks to this Zenas BioPharma narrative.

    Next Steps

    Mixed signals on Zenas BioPharma so far, with both concern and optimism in the mix, so review the data for yourself, including the 1 key reward and 3 important warning signs.

    Looking for more investment ideas beyond Zenas BioPharma?

    If Zenas BioPharma has your attention, round out your watchlist with a few more focused ideas so you are not relying on a single bet.